Chemotherapy Patient Articles & Analysis
17 news found
The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from the addition of tremelimumab to durvalumab and chemotherapy. ...
Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and mesothelioma Eagle Pharmaceuticals, Inc. ...
For the nearly one-quarter who were mesenchymal, survival was 2.4-fold worse compared to the remaining non-mesenchymal patients. A future diagnostic test, based upon this signature and related clinical findings, potentially may be used to ‘upstage’ patients typically receiving only surgical reduction to become candidates for the addition of radiation ...
Wound Infection Statistics Some patients who visit an urgent care clinic for cuts or lacerations may later develop an infection. ...
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving ...
The study found that Cellworks biosimulation identifies novel biomarkers that predict therapy response in AML patients, which offers the opportunity to tailor FDA-approved chemotherapy regimens to each patient to improve disease control and minimize toxicity. ...
Leuko have created PointCheck™, a non-invasive white cell monitor, dedicated to improving quality of life and outcomes for cancer chemotherapy patients and others at risk of severe neutropenia. We will be working with Leuko to help with the development of their fast, portable and simple to use device. Their aim is that millions of immunosuppressed ...
The FT516 treatment regimen is designed to be administered in the outpatient setting. Patients in the dose-escalation stage had received a median of 3.5 prior lines of therapy and a median of three prior lines containing CD20-targeted therapy. As of the data cutoff date of October 18, 2021, four patients in the second dose cohort of 90 million cells per dose, ...
Based on this updated model, adding data from RxPONDER leads to further cost-savings and potentially improved outcomes by avoiding short- and long-term adverse effects of chemotherapy without increased distant recurrence risk. The findings show that chemotherapy can be spared for the majority of postmenopausal women, those with Recurrence Score® results 0-25, ...
In 22/24 patient tests (91%), the results demonstrated resistance to at least one drug on which the patient’s disease progressed in clinic. ...
In addition, the Oncotype DX test is incorporated in the node-negative and postmenopausal node-positive NCCN treatment algorithms with a recommendation of “strongly consider”, using cutoffs defined by the TAILORxiv and RxPONDER trials to select patients for chemotherapy treatment. NCCN is an alliance of 21 world-leading cancer centers dedicated to ...
Food & Drug Administration (FDA) for patients with HER2-mutated NSCLC.1 HTI recently released results from a phase 2 clinical trial demonstrating that pyrotinib showed promising antitumor activity in patients with HER2-mutant advanced NSCLC who were previously treated with chemotherapy. The drug received conditional approval in China for the ...
Overall, the findings revealed a 36% net decrease in chemotherapy recommendations among patients with node-negative disease and a 46% decrease in those with node-positive disease. ...
(NYSE: PFE) today announced topline results of the Phase III JAVELIN Gastric 100 study evaluating avelumab as first-line maintenance therapy following induction chemotherapy in patients with unresectable, locally advanced or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) cancer versus continuation of chemotherapy or best ...
The analysis also provides details on the outcomes of different chemotherapy regimens for the minority of patients who benefit from chemotherapy. ...
Neuropathic pain often occurs in amputees with what is known as “phantom limb syndrome,” chemotherapy patients and diabetics with nerve damage. “Things like a light touch or change in temperature can become very painful,” explains Joseph Foss, director of clinical research in the Clinic’s Anesthesiology Institute. ...
A University of Wyoming spin-out business has received a $150,000 Small Business Innovation Research (SBIR) grant to improve the effectiveness of drugs that can potentially help diabetes and cancer patients. GlycoBac will use the six-month grant from the National Institutes of Health (NIH) for research to improve the effectiveness of already developed glycoprotein drugs. ...